BiotechTube
Hinge Bio

Hinge Bio

San Diego, United States· Est.
hingebio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

Hinge Bio is a clinical-stage biotech advancing a novel antibody platform, GEM-DIMER™, aimed at overcoming limitations of current therapies in autoimmunity and oncology. Its lead asset, HB2198, has entered clinical development for systemic lupus erythematosus (SLE) and lupus nephritis following an FDA IND clearance in 2025. The company is led by an experienced team with a strong track record in drug development and has secured a key partnership with Kyorin Pharmaceutical for the Japanese market. Hinge Bio represents a promising player in the development of multifunctional biologics.

Autoimmune DiseasesInflammatory DiseasesCancer

Technology Platform

GEM-DIMER™ platform for creating multifunctional antibody-based therapeutics with novel functionalities aimed at improving efficacy, overcoming resistance, and reducing side effects.

Funding History

2
Total raised:$30M
Series A$26M
Seed$4M

Opportunities

The large and growing global markets for autoimmune and oncology therapeutics present a significant opportunity for differentiated products.
The GEM-DIMER™ platform's potential to create best-in-class assets against validated targets could lead to high-value partnerships and rapid pipeline expansion.
The recent IND clearance and partnership with Kyorin validate the approach and provide a pathway to the Japanese market.

Risk Factors

The company faces high clinical development risk as its lead candidate enters first-in-human trials, with safety and efficacy yet to be proven.
As a private, pre-revenue company, it is dependent on external financing to fund operations and clinical trials.
It operates in highly competitive therapeutic areas with numerous established and emerging competitors.

Competitive Landscape

Hinge Bio competes in the crowded antibody therapeutics space, facing competition from large biopharma companies with extensive resources and portfolios, as well as other biotechs developing novel biologics for autoimmunity and cancer. Its differentiation hinges on the unique functionalities promised by the GEM-DIMER™ platform, which must demonstrate clinical superiority over existing B-cell depleters (e.g., rituximab) and other novel mechanisms.

More companies in Biologics / Biosimilars →More companies in United States →